These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 1303908)
41. A 2-year follow up of babies enrolled in a European multicentre trial of porcine surfactant replacement for severe neonatal respiratory distress syndrome. Collaborative European Multicentre Study Group. Robertson B; Curstedt T; Tubman R; Strayer D; Berggren P; Kok J; Koppe J; van Sonderen L; Halliday H; McClure G Eur J Pediatr; 1992 May; 151(5):372-6. PubMed ID: 1396894 [TBL] [Abstract][Full Text] [Related]
42. A simplified surfactant dosing procedure in respiratory distress syndrome: the "side-hole" randomized study. Spanish Surfactant Collaborative Group. Valls-i-Soler A; López-Heredia J; Fernández-Ruanova MB; Gastiasoro E Acta Paediatr; 1997 Jul; 86(7):747-51. PubMed ID: 9240884 [TBL] [Abstract][Full Text] [Related]
43. [Clinical characteristics and outcomes of respiratory distress syndrome in term and late-preterm neonates]. Chen A; Shi LP; Zheng JY; Du LZ Zhonghua Er Ke Za Zhi; 2008 Sep; 46(9):654-7. PubMed ID: 19099850 [TBL] [Abstract][Full Text] [Related]
44. Intratracheal atomized surfactant provides similar outcomes as bolus surfactant in preterm lambs with respiratory distress syndrome. Milesi I; Tingay DG; Zannin E; Bianco F; Tagliabue P; Mosca F; Lavizzari A; Ventura ML; Zonneveld CE; Perkins EJ; Black D; Sourial M; Dellacá RL Pediatr Res; 2016 Jul; 80(1):92-100. PubMed ID: 26954481 [TBL] [Abstract][Full Text] [Related]
45. Effects of surfactant treatment on gas-exchange and clinical course in near-term newborns with RDS. Golombek SG; Truog WE J Perinat Med; 2000; 28(6):436-42. PubMed ID: 11155428 [TBL] [Abstract][Full Text] [Related]
46. The effectiveness of surfactant replacement therapy for preterm infants with respiratory distress syndrome. Lim WL; Lim CT; Chye JK Med J Malaysia; 1998 Dec; 53(4):376-84. PubMed ID: 10971981 [TBL] [Abstract][Full Text] [Related]
47. Effectiveness of curosurf for severe respiratory distress syndrome: a case-control study. Valls-i-Soler A; Lizarraga M; López de Heredia J; Roman L; Hernáez E; Gastiasoro E Biol Neonate; 1992; 61 Suppl 1():21-5. PubMed ID: 1391261 [TBL] [Abstract][Full Text] [Related]
48. Pulmonary effects after surfactant treatment in premature infants with severe respiratory distress syndrome. Farstad T; Bratlid D Biol Neonate; 1995; 68(4):246-53. PubMed ID: 8580215 [TBL] [Abstract][Full Text] [Related]
49. Observational study to compare the clinical efficacy of the natural surfactants Alveofact and Curosurf in the treatment of respiratory distress syndrome in premature infants. Proquitté H; Dushe T; Hammer H; Rüdiger M; Schmalisch G; Wauer RR Respir Med; 2007 Jan; 101(1):169-76. PubMed ID: 16698258 [TBL] [Abstract][Full Text] [Related]
50. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Collaborative European Multicenter Study Group. Pediatrics; 1988 Nov; 82(5):683-91. PubMed ID: 2903480 [TBL] [Abstract][Full Text] [Related]
51. Late Surfactant Administration in Very Preterm Neonates With Prolonged Respiratory Distress and Pulmonary Outcome at 1 Year of Age: A Randomized Clinical Trial. Hascoët JM; Picaud JC; Ligi I; Blanc T; Moreau F; Pinturier MF; Zupan V; Guilhoto I; Hamon IR; Alexandre C; Bouissou A; Storme L; Patkai J; Pomedio M; Rouabah M; Coletto L; Vieux R JAMA Pediatr; 2016 Apr; 170(4):365-72. PubMed ID: 26928567 [TBL] [Abstract][Full Text] [Related]
52. Surfactant replacement therapy and the prevalence of acute retinopathy of prematurity. Tubman TR; Rankin SJ; Halliday HL; Johnston SS Biol Neonate; 1992; 61 Suppl 1():54-8. PubMed ID: 1391267 [TBL] [Abstract][Full Text] [Related]
53. Laryngeal mask airway used as a delivery conduit for the administration of surfactant to preterm infants with respiratory distress syndrome. Trevisanuto D; Grazzina N; Ferrarese P; Micaglio M; Verghese C; Zanardo V Biol Neonate; 2005; 87(4):217-20. PubMed ID: 15650304 [TBL] [Abstract][Full Text] [Related]
54. Mortality, severe respiratory distress syndrome, and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf. Egberts J; Brand R; Walti H; Bevilacqua G; Bréart G; Gardini F Pediatrics; 1997 Jul; 100(1):E4. PubMed ID: 9200378 [TBL] [Abstract][Full Text] [Related]
55. Raised plasma hypoxanthine levels as a prognostic sign in preterm babies with respiratory distress syndrome treated with natural surfactant. Saugstad OD; Tubman TR; Gloppestad K; Halliday HL; Oyasaeter S; Curstedt T; Robertson B J Perinat Med; 1992; 20(5):379-85. PubMed ID: 1479521 [TBL] [Abstract][Full Text] [Related]
56. Prognostic value of the immediate response to surfactant. Kuint J; Reichman B; Neumann L; Shinwell ES Arch Dis Child Fetal Neonatal Ed; 1994 Nov; 71(3):F170-3. PubMed ID: 7820711 [TBL] [Abstract][Full Text] [Related]
57. Curosurf surfactant application on preterm babies with respiratory complications-health-economic benefits. Mihaylova A; Kristina K; Kasnakova P; Gueorguiev S; Gueorguieva P; Bakova D; Parahuleva N Afr Health Sci; 2024 Mar; 24(1):220-227. PubMed ID: 38962356 [TBL] [Abstract][Full Text] [Related]